| Bioactivity | Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1]. | ||||||||||||
| Target | IC50: 8.9 nM (BTK) | ||||||||||||
| In Vivo | Evobrutinib (0.3, 1, 3, 10, or 30 mg/kg, oral gavage, once daily) demonstrates efficacy in a rat model of rheumatoid arthritis[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: | ||||||||||||
| CAS | 1415823-73-2 | ||||||||||||
| Formula | C25H27N5O2 | ||||||||||||
| Molar Mass | 429.51 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Caldwell R, et al. Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Aug 1. |
Evobrutinib
CAS: 1415823-73-2 F: C25H27N5O2 W: 429.51
Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.